Assessment of Response to a Third Dose of the SARS-CoV-2 BNT162b2 mRNA Vaccine in Patients With Solid Tumors Undergoing Active Treatment

JAMA Oncol. 2022 Feb 1;8(2):300-301. doi: 10.1001/jamaoncol.2021.6764.

Abstract

This cohort study evaluates the short-term humoral response to a third dose of the SARS-CoV-2 BNT162b2 vaccine in patients undergoing acute systemic therapy for solid tumors.

MeSH terms

  • BNT162 Vaccine
  • COVID-19*
  • Humans
  • Neoplasms* / drug therapy
  • SARS-CoV-2
  • Vaccines, Synthetic
  • mRNA Vaccines

Substances

  • Vaccines, Synthetic
  • mRNA Vaccine
  • mRNA Vaccines
  • BNT162 Vaccine